Page last updated: 2024-11-11

spiraeoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

spiraeoside: from flowers of Filipendula ulmaria (L.); structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

quercetin 4'-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 4'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Ulmariagenus[no description available]RosaceaeThe rose plant family in the order ROSALES and class Magnoliopsida. They are generally woody plants. A number of the species of this family contain cyanogenic compounds.[MeSH]
FilipendulagenusA plant genus of the family ROSACEAE. Members contain TANNINS.[MeSH]RosaceaeThe rose plant family in the order ROSALES and class Magnoliopsida. They are generally woody plants. A number of the species of this family contain cyanogenic compounds.[MeSH]
Filipendula ulmariaspecies[no description available]RosaceaeThe rose plant family in the order ROSALES and class Magnoliopsida. They are generally woody plants. A number of the species of this family contain cyanogenic compounds.[MeSH]

Cross-References

ID SourceID
PubMed CID5320844
CHEMBL ID402947
CHEBI ID75839
SCHEMBL ID1155660
MeSH IDM0215335

Synonyms (49)

Synonym
einecs 243-614-6
2-(4-(beta-d-glucopyranosyloxy)-3-hydroxyphenyl)-3,5,7-trihydroxy-4h-1-benzopyran-4-one
spiraein
quercetin 4'-o-glucoside
spiraeosid
spiraein (acacia)
4h-1-benzopyran-4-one, 2-(4-(beta-d-glucopyranosyloxy)-3-hydroxyphenyl)-3,5,7-trihydroxy-
NCGC00163625-01
spiraeoside
20229-56-5
CHEMBL402947 ,
chebi:75839 ,
quercetin 4'-o-beta-d-glucoside
3,5,7-trihydroxy-2-[3-hydroxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
bdbm50362884
unii-k2b74751xi
k2b74751xi ,
quercetin-4'-glucoside
spireoside
spiraeoside [inci]
quercetin 4'-.beta.-d-glucopyranoside
4h-1-benzopyran-4-one, 2-(4-(.beta.-d-glucopyranosyloxy)-3-hydroxyphenyl)-3,5,7-trihydroxy-
quercetin 4'-monoglucoside
spiraeoside [who-dd]
luteolin 4'-.beta.-d-glucoside
2-hydroxy-4-(3,5,7-trihydroxy-4-oxo-4h-chromen-2-yl)phenyl beta-d-glucopyranoside
quercetin 4'-o-beta-d-glucopyranoside
SCHEMBL1155660
mfcd00221723
AKOS025146959
OIUBYZLTFSLSBY-HMGRVEAOSA-N
4h-1-benzopyran-4-one, 2-[4-(.beta.-d-glucopyranosyloxy)-3-hydroxyphenyl]-3,5,7-trihydroxy-
quercetin 4'-b-d-glucoside
DTXSID00174078 ,
3,5,7-trihydroxy-2-(3-hydroxy-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-4h-chromen-4-one
spiraeoside, analytical standard
quercetin 4'-glucoside
spireoside (6ci,7ci,8ci)
J-013135
Q7577713
D85150
MS-28545
CS-0141978
HY-N8253
4h-1-benzopyran-4-one, 2-[4-(beta-d-glucopyranosyloxy)-3-hydroxyphenyl]-3,5,7-trihydroxy-
spiraeoside (constituent of hawthorn leaf with flower)
luteolin 4'-beta-d-glucoside
dtxcid5096569
quercetin 4'-beta-d-glucopyranoside

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" There was no significant difference in the bioavailability and pharmacokinetic parameters between the onion supplement and quercetin-4'-O-glucoside."( Pharmacokinetics and bioavailability of quercetin glycosides in humans.
Derendorf, H; Drewelow, B; Graefe, EU; Jacobasch, G; Mueller, S; Pforte, H; Riethling, AK; Uehleke, B; Veit, M; Wittig, J, 2001
)
0.31

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of the rutinoside was only 20% of that of the glucoside."( The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man.
Bijsman, MN; Cnossen, EP; de Vries, JH; Hollman, PC; Katan, MB; van Gameren, Y, 1999
)
0.3
" The sugar moiety in quercetin glycosides affects their bioavailability in humans."( Bioavailabilities of quercetin-3-glucoside and quercetin-4'-glucoside do not differ in humans.
Hollman, PC; Katan, MB; Olthof, MR; Vree, TB, 2000
)
0.31
" However, the bioavailability of these compounds is questionable."( Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption.
Otake, Y; Walle, T; Walle, UK; Wilson, FA, 2000
)
0.31
" However, data on the bioavailability of quercetin after oral intake are scarce and contradictory."( Pharmacokinetics and bioavailability of quercetin glycosides in humans.
Derendorf, H; Drewelow, B; Graefe, EU; Jacobasch, G; Mueller, S; Pforte, H; Riethling, AK; Uehleke, B; Veit, M; Wittig, J, 2001
)
0.31
" The poor bioavailability of important dietary quercetin glycosides has implications for their in vivo bioactivities."( The type of sugar moiety is a major determinant of the small intestinal uptake and subsequent biliary excretion of dietary quercetin glycosides.
Arts, IC; Faassen-Peters, M; Hollman, PC; Sesink, AL, 2004
)
0.32
" These compounds have a wide range of potential health benefits, and understanding the bioavailability of flavonoids from foods is becoming increasingly important."( In vitro digestion and lactase treatment influence uptake of quercetin and quercetin glucoside by the Caco-2 cell monolayer.
Boyer, J; Brown, D; Liu, RH, 2005
)
0.33
" Despite the loss of quercetin from the digested shallot, the bioavailability of quercetin aglycone to the Caco-2 cells was the same in both the digested and non-digested shallot."( In vitro digestion and lactase treatment influence uptake of quercetin and quercetin glucoside by the Caco-2 cell monolayer.
Boyer, J; Brown, D; Liu, RH, 2005
)
0.33
"The increase in quercetin uptake following treatment with lactase suggests that dietary supplementation with lactase may increase quercetin bioavailability in lactose intolerant humans."( In vitro digestion and lactase treatment influence uptake of quercetin and quercetin glucoside by the Caco-2 cell monolayer.
Boyer, J; Brown, D; Liu, RH, 2005
)
0.33
" The bioavailability of flavonoids from fruits and vegetables is frequently affected by the manufacturing process and related conditions."( Effect of Processed Onions on the Plasma Concentration of Quercetin in Rats and Humans.
Hamano, T; Kashino, Y; Matsuda, N; Mukai, R; Murota, K; Terao, J; Tomotake, M, 2015
)
0.42
" The present study estimated the effect of food processing on the bioavailability of onion quercetin aglycone and its glucosides provided through the consumption of onion products."( Effect of Processed Onions on the Plasma Concentration of Quercetin in Rats and Humans.
Hamano, T; Kashino, Y; Matsuda, N; Mukai, R; Murota, K; Terao, J; Tomotake, M, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
beta-D-glucosideAny D-glucoside in which the anomeric centre has beta-configuration.
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
quercetin O-glucosideA quercetin O-glycoside that is an O-glucosylated derivative of quercetin.
tetrahydroxyflavoneAny hydroxyflavone carrying four hydroxy substituents.
flavonolsAny hydroxyflavone in which is the ring hydrogen at position 3 of the heterocyclic ring is replaced by a hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency19.95260.003245.467312,589.2998AID2517
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency35.48130.036619.637650.1187AID2112
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)95.31000.00101.191310.0000AID639825
Aurora kinase BHomo sapiens (human)IC50 (µMol)29.37000.00030.96349.8000AID1801097
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID1233224Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 30 uM after 72 hrs by microplate reader analysis relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1417094Inhibition of recombinant oligo-histidine-tagged Leishmania major DHODH expressed in Escherichia coli BL21(DE3) cells using DHO as substrate measured after 60 secs2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1168660Antiviral activity against Dengue virus assessed as inhibition of viral replication2014European journal of medicinal chemistry, Nov-24, Volume: 87A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.
AID1171182Teratogenic effect in zebrafish assessed as abnormal heart at 160 uM after 72 hrs by microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1171179Induction of apoptosis in human HCT116 cells assessed as PARP cleavage at 20 uM after 72 hrs by immunoblotting2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1233231Cytotoxicity against mouse B16-4A5 cells assessed as cell viability at 100 uM after 70 hrs by WST-8 assay relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1233227Cytotoxicity against mouse B16-4A5 cells assessed as cell viability at 1 uM after 70 hrs by WST-8 assay relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1233230Cytotoxicity against mouse B16-4A5 cells assessed as cell viability at 30 uM after 70 hrs by WST-8 assay relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1171187Teratogenic effect in zebrafish assessed as developmental toxicity at 40 to 80 uM after 72 hrs by microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1233223Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 10 uM after 72 hrs by microplate reader analysis relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1233244Inhibition of plasmin (unknown origin) at 100 uM after 18 hrs by arianor mahogany dye-based fibrin plate assay relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1233233Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 100 uM after 5 mins by microplate reader analysis relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1171186Teratogenic effect in zebrafish assessed as abnormal development of yolk sac at 160 uM after 72 hrs by microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1233225Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 100 uM after 72 hrs by microplate reader analysis relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1171184Teratogenic effect in zebrafish assessed as slow heartbeat at 160 uM after 72 hrs by microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1233226Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1171181Teratogenic effect in zebrafish assessed as skeletal deformities at 160 uM after 72 hrs by microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1171178Cytotoxicity against human HCT116 cells at 1.25 to 20 uM after 96 hrs by MTT assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1233232Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 10 uM after 5 mins by microplate reader analysis relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1171188Antitumor activity against human HCT116 cells xenografted in 48 hpf zebrafish embryo assessed as inhibition of cancer cell proliferation at 80 uM treated for 4 days2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1233222Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 3 uM after 72 hrs by microplate reader analysis relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID317348Drug level in human plasma2008Bioorganic & medicinal chemistry, Feb-15, Volume: 16, Issue:4
The effect of flavonoid derivatives on doxorubicin transport and metabolism.
AID639825Inhibition of human recombinant aldose reductase using D-glyceraldehyde as substrate preincubated for 10 mins before substrate addition measured for every 10 secs for 50 mins by spectrophotometry2012Bioorganic & medicinal chemistry, Feb-01, Volume: 20, Issue:3
Construction of an Indonesian herbal constituents database and its use in Random Forest modelling in a search for inhibitors of aldose reductase.
AID1171190Drug metabolism assessed as zebrafish intestinal beta-glucosidase-mediated deglycosylation of compound at 80 uM after 2.5 hrs by resorufin-beta-D-glucopyranoside-based fluorescence assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1171185Teratogenic effect in zebrafish assessed as heart sac edema at 160 uM after 72 hrs by microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1417091Inhibition of human DHODH at 100 uM2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1171180Teratogenic effect in zebrafish assessed as delayed hatching at 160 uM after 72 hrs by microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1233228Cytotoxicity against mouse B16-4A5 cells assessed as cell viability at 3 uM after 70 hrs by WST-8 assay relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1233229Cytotoxicity against mouse B16-4A5 cells assessed as cell viability at 10 uM after 70 hrs by WST-8 assay relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1171183Teratogenic effect in zebrafish assessed as abnormal head at 160 uM after 72 hrs by microscopy2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Delineation of the role of glycosylation in the cytotoxic properties of quercetin using novel assays in living vertebrates.
AID1233221Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 1 uM after 72 hrs by microplate reader analysis relative to control2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Inhibitors of melanogenesis in B16 melanoma 4A5 cells from flower buds of Lawsonia inermis (Henna).
AID1417093Inhibition of recombinant oligo-histidine-tagged Leishmania major DHODH expressed in Escherichia coli BL21(DE3) cells at 100 uM using DHO as substrate measured after 60 secs2018European journal of medicinal chemistry, Sep-05, Volume: 157Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1801097Aurora B Kinase Assay from Article 10.1111/cbdd.12445: \\Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.\\2015Chemical biology & drug design, May, Volume: 85, Issue:5
Plant-derived flavones as inhibitors of aurora B kinase and their quantitative structure-activity relationships.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (10.87)18.2507
2000's22 (47.83)29.6817
2010's15 (32.61)24.3611
2020's4 (8.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.42 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (12.77%)5.53%
Reviews1 (2.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (85.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]